Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions driven by neural hyperexcitability. The company highlighted progress on multiple clinical programs, including OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 results for OV329 demonstrated a strong safety profile and pharmacodynamic activity, with Phase 2a initiation expected in the second quarter of 2026 and topline results anticipated in mid-2027. Ovid also reported on OV350 IV, a first-in-human direct activator of KCC2, with Phase 1 topline findings expected in the fourth quarter of 2025. Other pipeline candidates include OV4071 for psychosis associated with Parkinson's disease, Lewy body dementia, and schizophrenia, with regulatory submissions and Phase 1 studies planned for 2026, and OV4041 targeting generalized anxiety disorder and Rett syndrome, moving toward IND submission in late 2026. The company stated it has an anticipated cash runway into the second half of 2028, supporting advancement of these programs. You can access the full presentation through the link below.